去势联合高强度聚焦超声治疗晚期前列腺癌对患者生存及免疫状态的影响

武睿毅; 王国民; 徐磊; 徐叶青

去势联合高强度聚焦超声治疗晚期前列腺癌对患者生存及免疫状态的影响

- 复旦大学附属中山医院泌尿外科(上海, 200032)
基金项目:
教育部高等学校博士学科点专项科研基金新教师基金（No：200802461036）

详细信息

通讯作者: 王国民,E-mail:wang.guomin@zs-hospital.sh.cn

中图分类号: R737.25

收稿日期: 2011-02-16

The influence of castration in combination with high intensity focused ultrasound treatment on survival and immune state of patients with advanced prostate cancer

- Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China

More Information

Corresponding author: WANG Guomin, E-mail: wang.guomin@zs-hospital.sh.cn

Received Date: 16 February 2011

摘要

摘要: 目的：探索晚期前列腺癌（prostate cancer，PCa）去势后，联合高强度聚焦超声（HIFU）局部治疗原发灶对患者生存和免疫状态的影响。方法：我院于2000年3月~2010年12月对64例晚期PCa去势手术后的患者进行前瞻性对照非随机研究，对照组30例接受单纯内分泌治疗，HIFU组34例去势后联合HIFU治疗。绘制两组患者的Kaplan-Meier生存曲线和并计算生存率，进行生存分析。部分患者（对照组11例，HIFU组12例）于治疗前、后采取外周血检测免疫指标，包括IL-2、IFN-γ、VEGF、TGF-β1和CD4⁺CD25⁺Foxp3⁺细胞水平。结果：对照组3年和5年生存率为45.19%和25.83%，HIFU组3年和5年生存率为76.92%和51.26%，两组的生存曲线差异有统计学意义（P=0.0404）。与对照组比较，HIFU组患者治疗后的外周血IL-2（P=0.042）、IFN-γ（P=0.019）水平显著提高，VEGF （P=0.032）、TGF-β1（P=0.042）水平和CD4⁺CD25⁺Foxp3⁺细胞（%）（P=0.001）显著降低。结论：晚期PCa去势后联合HIFU局部治疗原发灶能提高患者对内分泌治疗的反应，并能改善机体的免疫状态，显著延长了患者的生存时间。
- 前列腺癌 /
- 高强度聚焦超声 /
- 局部治疗 /
- 生存分析 /
- 免疫
Abstract: Objective: To explore the influence of castration in combination with high intensity focused ultrasound(HIFU)treatment on survival and immune state of patients as local therapy for advanced prostate cancer.Method: Between March 2000 and December 2010,we performed a prospective,controlled,and nonrandomized study on 64 patients with advanced PCa after hormonal therapy.30 cases in control group received hormonal therapy alone,and 34 cases in HIFU group received HIFU treatment following castration.To make survival analyses by the method of Kaplan-Meier survival curves and calculating survival rates.Some patients(control group 11 cases,HIFU group 12 cases)were detected the immunity index of peripheral blood before and after treatments,including IL-2,IFN-γ,VEGF,TGF-β1 and CD4⁺CD25⁺Foxp3⁺ cell.Result: The 3-year and 5-year survival rates of control group were 45.19% and 25.83%,and those of HIFU group were 76.92% and 51.26%.There was significant difference between two groups in survival curve(P=0.0404).Compared with control group,IL-2(P=0.042)and IFN-γ(P=0.019)level of peripheral blood in HIFU group significantly rose,and VEGF(P=0.032),TGF-β1(P=0.042)level and CD4⁺CD25⁺Foxp3⁺(%)(P=0.001)significantly decreased.Conclusion: After castration treatment for advanced prostate cancer,combination with HIFU to strengthen local control of primary lesions could enhanced the therapeutic response of patients to hormone therapy,also improved systemic immune state,significantly prolonged the survival time of patients..
- prostate cancer /
- high-intensity focused ultrasound /
- local treatment /
- survival analysis /
- immunity

HTML全文

参考文献(13)

[1]	CHANG S S,KIBEL A S.The role of systemic cytotoxic therapy for prostate cancer[J].BJU Int,2009,103:8-17.
[2]	[CM(22*2] PEETERS S T, HEEMSBERGEN W D, VAN PUTTEN W L, et al. Acute and late complications after radiotherapy for prostate cancer:results of a multicenter randomized trial comparing 68 Gy to 78 Gy[J]. Int J Radiat Oncol Biol Phys, 2005, 61:1019-1034.
[3]	VERHAGEN P C, SCHRÖDER F H, COLLETTE L, et al. Does local treatment of the prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy? A systematic review[J].Eur Urol,2010,58:261-269.
[4]	KENNEDY J E.High-intensity focused ultrasound in the treatment of solid tumours[J].Nat Rev Cancer,2005,5:321-327.
[5]	ZHOU Q,ZHU X Q,ZHANG J,et al.Changes in circulating immunosuppressive cytokine levels of cancer patients after high intensity focused ultrasound treatment[J].Ultrasound Med Biol,2008,34:81-87.
[6]	HU Z,YANG X Y,LIU Y,et al.Release of endogenous danger signals from HIFU-treated tumor cells and their stimulatory effects on APCs[J].Biochem Biophys Res Commun,2005,335:124-131.
[7]	CHEVILLE J C,TINDALL D,BOELTER C,et al.Metastatic prostate carcinoma to bone:clinical and pathologic features associated with cancer-specific survival[J].Cancer,2002,95:1028-1036.
[8]	ZIETMAN A L,COEN J J,DALLOW K C,et al.The treatment of prostate cancer by conventional radiation therapy:an analysis of long-term outcome[J].Int J Radiat Oncol Biol Phys,1995,32:287-292.
[9]	UCHIDA T,SANGHVI N T,GARDNER T A,et al.Transrectal high-intensity focused ultrasound for treatment of patients with stage T1b-2N0M0 localized prostate cancer:a preliminary report[J].Urology,2002,59:394-398; discussion 398-399.
[10]	CHAUSSY C,THVROFF S.Results and side effects of high-intensity focused ultrasound in localized prostate cancer[J].J Endourol,2001,15:437-440; discussion 447-448.
[11]	ADLER A J.Mechanisms of T cell tolerance and suppression in cancer mediated by tumor-associated antigens and hormones[J].Curr Cancer Drug Targets,2007,7:3-14.
[12]	陈广洁.Foxp3和CD4⁺CD25⁺调节性T细胞研究进展[J].国外医学免疫学分册,2005,28(1):1-4.
[13]	BLANA A,ROGENHOFER S,GANZER R,et al.Morbidity associated with repeated transrectal high-intensity focused ultrasound treatment of localized prostate cancer[J].World J Urol,2006,24:585-590.